Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Predictive factors of response to anti-CGRP pathway drugs in people with multiple sclerosis.

The journal of headache and pain·2026

Same author

Cerebrovascular reactivity and plasma p-tau181 in Alzheimer's disease: Insights into APOE-related vascular phenotypes.

Alzheimer's & dementia (New York, N. Y.)·2026

Same author

Alzheimer's Disease Cerebrospinal Fluid Biomarkers Predict Survival in Progressive Supranuclear Palsy.

Movement disorders : official journal of the Movement Disorder Society·2026

Same author

Lateralization of interictal epileptiform discharges differently impacts cognitive performance and behavior in late-onset epilepsy of unknown aetiology.

Frontiers in aging neuroscience·2026

Same author

Prevalence of sleep and mood disorders in people with epilepsy: A single-Center self-reported assessment.

Epileptic disorders : international epilepsy journal with videotape·2026

Same author

Frequency- and Network-Specific Changes in Functional Connectivity Reflect Pathophysiological Mechanisms across Parkinson's Disease Stages.

Annals of neurology·2026

Same journal

Inhaled Levodopa for the Management of OFF Episodes in Patients with Parkinson's Disease: A Network Meta-analysis.

Neurology and therapy·2026

Same journal

Neurologists' Views on the Management of Uncontrolled Epilepsy in Spain: A Preliminary Survey.

Neurology and therapy·2026

Same journal

Polypharmacy, Potential Drug-Drug Interactions and Medication Non-Adherence in Patients with Multiple Sclerosis: A Longitudinal Study.

Neurology and therapy·2026

Same journal

AQP4-IgG Dynamics and Exploratory Assessment of SERA-3 in Neuromyelitis Optica Spectrum Disorder Treated with Satralizumab.

Neurology and therapy·2026

Same journal

Steroid-Sparing Effect of Efgartigimod in Generalized Myasthenia Gravis: Study Protocol for a Single-Arm, Open-Label Clinical Trial.

Neurology and therapy·2026

Same journal

Screening on the Paretic Side is Superior for Detecting Possible Sarcopenia in Individuals After Chronic Stroke: Preliminary Findings.

Neurology and therapy·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 4, 2026

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

Fingolimod Immune Effects Beyond Its Sequestration Ability.

Francesco Sica¹, Diego Centonze^2,3, Fabio Buttari¹

¹Unit of Neurology, IRCCS Neuromed, Pozzilli, IS, Italy.

Neurology and Therapy

|November 8, 2019

Summary

This summary is machine-generated.

Fingolimod, a multiple sclerosis (MS) treatment, alters lymphocyte distribution and function. It enhances regulatory B cells, potentially offering new therapeutic avenues for MS by influencing immune cell activity within the central nervous system.

Keywords:

B lymphocytes Fingolimod Mechanism of action T lymphocytes

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Related Experiment Videos

Last Updated: Jan 4, 2026

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Area of Science:

Immunology
Neuroscience
Pharmacology

Background:

Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
Fingolimod is an approved oral medication for relapsing-remitting MS, targeting sphingosine receptors.
Understanding fingolimod's immunomodulatory effects is crucial for optimizing MS treatment.

Purpose of the Study:

To elucidate the comprehensive effects of fingolimod on T and B lymphocyte populations in MS patients.
To investigate fingolimod's impact on regulatory lymphocyte subsets and their migration across the blood-brain barrier.
To explore novel therapeutic mechanisms of fingolimod in the context of MS pathogenesis.

Main Methods:

Analysis of lymphocyte subsets in peripheral blood and cerebrospinal fluid of MS patients.
Assessment of T-cell differentiation and cytokine production.
Evaluation of B-cell populations, including transitional and regulatory subsets.
Investigation of regulatory B-cell transmigration across endothelial cells.

Main Results:

Fingolimod treatment alters lymphocyte trafficking, sequestering naive T cells and central memory T cells in lymphoid organs.
The drug inhibits Th1 and Th17 cytokines while promoting regulatory T-cell differentiation.
Fingolimod modulates B-cell immunity, increasing naive to memory B-cell ratio and enhancing regulatory B-cell subsets.
Increased regulatory B-cell frequency in cerebrospinal fluid suggests enhanced CNS immune regulation.

Conclusions:

Fingolimod exerts multifaceted immunomodulatory effects beyond lymphocyte sequestration.
The drug enhances regulatory B-cell function and migration, potentially contributing to its therapeutic efficacy in MS.
These findings reveal a novel role for fingolimod in modulating both innate and adaptive immunity within the CNS for MS treatment.